Isn't DMA supposed to be the driver of new patients growth for ONT? Then how come it's been disposed?
Unexpectedly, this news has been relegated to page 18 in the notes of the report with zero explanation. The trend of burying anything that is not positive continues.... never to be mentioned again.
If only the CEO can tone down his "shareholder friendly" fluff and just walk the talk by telling us what happened and why it happened, I would it find reading his shareholders letter more palatable.
The reason behind it might be not that negative anyway and I imagine most shareholders would prefer to know the actual reasons, considering it's been hyped up so much for the past few years.
At least the company secretary who joined in January 2017 is still around....
ONT Price at posting:
$6.50 Sentiment: Sell Disclosure: Not Held